title: Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.
abstract: P73 is a structural and functional homologue of p53, and plays an important role in regulating cell cycle and apoptosis. A potentially functional polymorphism (designated as p73 G4C14-to-A4T14) has been identified in a region in exon 2 of the p73 gene, which may theoretically form a stem-loop structure and thereby affect p73 expression. Several investigations have reported the correlation between p73 G4C14-to-A4T14 polymorphism and cancer risk. However, the results are inconclusive. To further assess the association between p73 polymorphism and cancer risk, we performed meta-analysis of the data sets obtained from 26 individual studies involving 8,148 cancer patients and 8,150 controls. The association between p73 G4C14-to-A4T14 polymorphism and cancer risk was determined by crude odd ratios (OR) with 95% CI (confidential interval). AT-allele carriers were found to have a significantly increased risk of cervical cancer (AT/GC vs. GC/GC, OR = 1.63, 95% CI = 1.14-2.33; AT/AT + AT/GC vs. GC/GC, OR = 1.49, 95% CI = 1.05-2.10), colorectal cancer (AT/AT vs. AT/GC + GC/GC, OR = 1.98, 95% CI = 1.25-3.12), head and neck cancer (AT/AT + AT/GC vs. GC/GC, OR = 1.44, 95% CI = 1.06-1.96) and other cancers (AT/AT vs. GC/GC, OR = 1.78, 95% CI = 1.24-2.57; AT/AT vs. AT/GC + GC/GC, OR = 1.80, 95% CI = 1.26-2.56). In the stratified analysis of ethnicity, a significantly elevated cancer risk was found in Caucasians (AT/AT + AT/GC vs. GC/GC, OR = 1.18, 95% CI = 1.08-1.30; allele AT vs. allele GC, OR = 1.15, 95% CI = 1.06-1.24). No significant association of p73 polymorphism with the cancer risk of smoking was detected by stratified analysis by smoking status. Together, our data suggest that the p73 G4C14-to-A4T14 may be a risk factor of cancer especially in Caucasians.
authors: State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, People's Republic of China.
authors: Lan
authors: L
authors: Wang
authors: Rui
authors: R
authors: Gao
authors: Long
authors: L
authors: Yu
references: Cancer Res. 1999 Jul 1;59(13):3257-63
references: 10397274
references: Mol Cancer Res. 2004 Jul;2(7):371-86
references: 15280445
references: Int J Cancer. 2000 Oct 1;88(1):66-70
references: 10962441
references: Hum Mutat. 2003 Mar;21(3):182-91
references: 12619104
references: Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):592-3
references: 16537723
references: Eur J Cancer. 2007 Jun;43(9):1361-72
references: 17428654
references: Mutat Res. 2009 Apr 30;675(1-2):60-5
references: 19386249
references: BMC Cancer. 2009 May 08;9:137
references: 19426493
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Nat Genet. 2000 May;25(1):47-54
references: 10802655
references: Int J Gynecol Cancer. 2009 May;19(4):572-7
references: 19509552
references: Carcinogenesis. 2004 Oct;25(10):1911-6
references: 15180941
references: Virchows Arch. 2010 Sep;457(3):359-68
references: 20644956
references: Breast Cancer. 2003;10(4):307-11
references: 14634508
references: Oncogene. 1999 Feb 25;18(8):1629-33
references: 10102633
references: Clin Cancer Res. 2002 Jan;8(1):165-70
references: 11801554
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: Asian Pac J Cancer Prev. 2003 Apr-Jun;4(2):107-12
references: 12875622
references: Dis Esophagus. 2007;20(4):290-6
references: 17617876
references: Carcinogenesis. 2000 Apr;21(4):683-9
references: 10753204
references: Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):158-61
references: 16434604
references: Nature. 2000 Mar 2;404(6773):99-103
references: 10716451
references: Br J Cancer. 2001 Nov 16;85(10):1499-503
references: 11720435
references: Prostate. 2001 Sep 15;48(4):292-6
references: 11536309
references: J Exp Med. 2002 Sep 16;196(6):765-80
references: 12235210
references: Mol Biol Rep. 2011 Mar;38(3):1603-7
references: 20842446
references: Cell Growth Differ. 1998 Nov;9(11):897-903
references: 9831242
references: Cancer Res. 2004 Oct 1;64(19):6863-6
references: 15466174
references: Carcinogenesis. 2008 Nov;29(11):2120-5
references: 18701437
references: Cancer Lett. 2004 Mar 8;205(1):55-60
references: 15036661
references: Carcinogenesis. 2005 Jan;26(1):103-7
references: 15485994
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Cell. 1997 Aug 22;90(4):809-19
references: 9288759
references: Cancer Lett. 2002 Jul 8;181(1):81-5
references: 12430182
references: J Invest Dermatol. 2008 Jun;128(6):1585-8
references: 18049450
references: Jpn J Clin Oncol. 2003 May;33(5):215-20
references: 12865464
references: Clin Cancer Res. 2000 May;6(5):1767-71
references: 10815895
references: Mol Biol Rep. 2011 Jan;38(1):229-36
references: 20333547
references: Cancer Lett. 2005 Mar 10;219(2):183-90
references: 15723718
references: Hum Genet. 2009 Apr;125(3):239-46
references: 19214578
references: Int J Cancer. 2005 Apr 10;114(3):455-60
references: 15578704
references: Leuk Lymphoma. 2004 May;45(5):957-64
references: 15291355
references: Cancer Res. 2004 Apr 1;64(7):2449-60
references: 15059898
references: Biochem Genet. 2006 Dec;44(11-12):543-50
references: 17136456
references: Ai Zheng. 2006 Nov;25(11):1351-5
references: 17094900
references: Cancer Res. 1998 Jun 1;58(11):2347-9
references: 9622072
references: Cancer. 2008 Dec 15;113(12):3307-14
references: 18988287
references: Mol Carcinog. 2009 Sep;48(9):790-800
references: 19204927
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120